Rebus Holdings, Inc. (RBSH)

OTCMKTS: RBSH · Delayed Price · USD
-0.0001 (-0.41%)
Jul 1, 2022 4:00 PM EDT - Market open

Company Description

Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer.

Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.

Rebus Holdings, Inc.
Country United States
Founded 2003
Industry Biotechnology
Sector Health Care
Employees 1

Contact Details

2629 Townsgate Road
Westlake Village, CA 91361
United States
Phone 818 597 7552

Stock Details

Ticker Symbol RBSH
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001421204
ISIN Number US75619J1034

Key Executives

Name Position
Raul Silvestre Esq. Chief Executive Officer, Chief Financial Officer, President, Principal Accounting Officer and Director
Dr. John T. Isaacs Ph.D. Co-Founder, Chairman of Scientific Advisory Board and Chief Scientific Advisor
Dr. Samuel R. Denmeade M.D. Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board

Latest SEC Filings

Date Type Title
May 13, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Mar 31, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Dec 10, 2021 EFFECT Notice of Effectiveness
Dec 9, 2021 424B3 Prospectus [Rule 424(b)(3)]
Dec 8, 2021 CORRESP Correspondence
Dec 3, 2021 S-1/A General form for registration of securities under the Securities Act of 1933
Nov 12, 2021 10-Q Quarterly report [Sections 13 or 15(d)]
Oct 12, 2021 8-K/A Current report
Oct 12, 2021 8-K Current report
Oct 4, 2021 8-K Current report